Three papers on MDMA are retracted by medical journal, just a day after Lykos’ FDA rejection

Three articles detailing the mid-stage trial results of Lykos Therapeutics’ MDMA-assisted therapy were retracted by the medical journal that published them, citing a failure by …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

COMPASS Pathways Raises Up To $50 Million In Non-Dilutive Financing

Mental health psychedelics biotech company COMPASS Pathways CMPS received funding for its COMP360 Phase 3 program in Treatment-Resistant Depression (TRD). The company entered into a term loan agreement with Hercules Capital Inc. HTGC

July 5, 2023

A close collaboration to help children suffering from cancer

The close collaboration between the Paul Scherrer Institute PSI and the University Children’s Hospital Zurich for the benefit of children suffering from cancer began 20

July 8, 2024

Drug-Gene Interactions: Minimizing Risk with Pharmacogenomics

Houda Hachad, PharmD, Vice President of Clinical Operations at Aranscia Every individual responds differently to medications, and their reactions can vary greatly. While a specific

August 10, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.